title: HIV-gp120 and physical dependence to buprenorphine.
abstract: BACKGROUND
  Opioids are among the most effective and commonly used analgesics in clinical practice for severe pain. However, the use of opioid medications is clinically limited by several adverse properties including dependence. While opioid dependence is a complex health condition, the treatment of HIV-infected individuals with opioid dependence presents additional challenges. The goal of this study was to examine the physical dependence to buprenorphine in the context of HIV.
  
  
  METHODS
  Young adult male rats (Sprague-Dawley) were pretreated with HIV-1 envelope glycoprotein 120 (gp120) injected into the periaqueductal gray area (PAG) and we examined the impact on physical dependence to opioid.
  
  
  RESULTS
  It was found that the physical dependence to methadone occurred earlier than that to buprenorphine, and that gp120 did not enhance or precipitate the buprenorphine withdrawal.
  
  
  CONCLUSIONS
  The results suggest that buprenorphine could be the better therapeutic option to manage opioid dependence in HIV.
authors.affiliation: Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, United States.
authors.forename: J
authors.initials: J
authors.lastname: Palma
authors.affiliation: Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, United States.
authors.forename: M E
authors.initials: ME
authors.lastname: Abood
authors.affiliation: Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, TX 79430, United States; Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, United States. Electronic address: khalid.benamar@ttuhsc.edu.
authors.forename: K
authors.initials: K
authors.lastname: Benamar
mesh_terms: D000818:Animals; D002047:Buprenorphine / Q000009:adverse effects* / Q000627:therapeutic use; D015699:HIV Envelope Protein gp120 / Q000494:pharmacology*; D015658:HIV Infections / Q000150:complications; D008297:Male; D008691:Methadone / Q000009:adverse effects* / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000150:complications*; D010146:Pain / Q000150:complications / Q000188:drug therapy; D010487:Periaqueductal Gray / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D015699:HIV Envelope Protein gp120; D002047:Buprenorphine; D008691:Methadone
keywords: Buprenorphine; HIV-1; Methadone; Physical dependence; gp120